Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
Holding ARDX?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
<$0.01Last Year’s EPS
-$0.12Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -17.89%
|Next Earnings Date:Mar 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and strong market reception for Ardelyx's products, IBSRELA and XPHOZAH. However, challenges remain with CMS coverage uncertainties and increased operating expenses. Legal and legislative efforts to address policy changes are ongoing.Company Guidance
In the Ardelyx third quarter 2024 earnings call, the company provided guidance highlighting the strong performance of their products, IBSRELA and XPHOZAH. IBSRELA recorded a 15% increase in net sales over the previous quarter, with expectations for full-year 2024 U.S. net product sales revenue to be between $145 million and $150 million. Growth metrics for IBSRELA included increases in new and refill prescriptions and new and repeat prescribers. XPHOZAH also demonstrated significant growth, with a 39% increase in net sales revenue quarter-over-quarter, totaling $51.5 million. The company is addressing uncertainties in Medicare coverage for XPHOZAH by pursuing legal, legislative, and commercial strategies to ensure patient access. Ardelyx maintains a strong cash position with over $240 million, supporting their future growth initiatives.Strong Revenue Growth
Ardelyx reported $98.2 million in total revenue during Q3 2024, a significant increase from $56.4 million in the same period in 2023.
IBSRELA Sales Surge
Net product sales revenue for IBSRELA was $40.6 million, nearly double from the same period in 2023 and a 15% quarter-over-quarter growth.
XPHOZAH Exceptional Launch
XPHOZAH reported $51.5 million in net product sales revenue for Q3 2024, a 39% increase quarter-over-quarter.
Strong Cash Position
Ardelyx finished Q3 2024 with a cash position of $240 million, including a $50 million draw from a debt agreement.
Positive Market Reception
Strong demand and positive market reception for IBSRELA and XPHOZAH at industry events like the American College of Gastroenterology and ASN.
---
ARDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $5.87 | $6.09 | +3.75% |
| Aug 01, 2024 | $5.50 | $6.05 | +10.00% |
| May 02, 2024 | $6.79 | $8.72 | +28.42% |
| Feb 22, 2024 | $8.82 | $8.68 | -1.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ardelyx (ARDX) report earnings?
Ardelyx (ARDX) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Ardelyx (ARDX) earnings time?
Ardelyx (ARDX) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARDX EPS forecast?
ARDX EPS forecast for the fiscal quarter 2024 (Q4) is <$0.01.
---
